close

Agreements

Date: 2012-06-20

Type of information: Development agreement

Compound: lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets

Company: CellCentric (UK) ZoBio (The Netherlands)

Therapeutic area: Cancer - Oncology

Type agreement:

development
services

Action mechanism:

Starting with its core TINS (Target Immobilized NMR Screening) fragment screening technology, ZoBio provides an array of biophysics services to support fragment-based drug discovery. These services form an integrated pipeline that includes fragment discovery, validation/characterisation by orthogonal methods such as SPR, and NMR-based structural biology services. ZoBio has used its cutting edge capabilities to discover fragment inhibitors for variety of targets including kinases, protein-protein interaction, anti-virals and membrane proteins such as GPCRs and ligand gated ion channels.

Disease: cancer

Details:

ZoBio and CellCentric,  a drug discovery company focused on targeting epigenetic processes for new treatments for cancer, have announced a collaboration to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets. ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric. Hit to lead and lead optimisation activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.
CellCentric identifies novel cellular mechanisms and targets which it then prioritises and takes into small molecule drug discovery. Active programmes include inhibitors to histone methyltransferases and epigenetic enzymes that act via ubiquitination.

Financial terms:

Latest news:

Is general: Yes